The Huntington's Disease Treatment Market is Predict to reach USD 805.1 Million by 2031, at a CAGR of 9.0%

Huntington’s Disease Treatment Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global size is expected to reach $805.1 million by 2031, rising at a market growth of 9.0% CAGR during the forecast period.

The encompasses pharmaceuticals, therapies, and healthcare services dedicated to addressing the symptoms and underlying causes of Huntington’s disease (HD). Treatments for HD encompass a variety of therapeutic approaches aimed at managing symptoms, slowing disease progression, and potentially modifying the course of the disease. These applications span symptomatic management, disease-modifying therapies, supportive care, and emerging strategies focused on neuroprotection and personalized medicine.

The Approved Drugs segment is registering a CAGR of 8.9 % during the forecast period. Huntington's Disease (HD) is a rare and complex neurological condition with limited treatment options. Approved drugs provide crucial therapeutic interventions to manage symptoms and improve the quality of life for patients living with HD.

The Hospital Pharmacies segment led the Global by Distribution Channel in 2023; thereby, achieving a market value of $447.2 Million by 2031. Hospital pharmacies often have access to specialized healthcare professionals, including neurologists, psychiatrists, and multidisciplinary teams with expertise in managing complex neurodegenerative diseases like HD.

The Below 50 years segment is growing at a CAGR of 8.8 % during the forecast period. Huntington’s Disease typically manifests symptoms during adulthood, with the onset usually occurring between 30 to 50 years of age. Therefore, individuals in this age group are more likely to experience symptoms and seek medical intervention for diagnosis, symptom management, and treatment.

Full Report: https://www.kbvresearch.com/huntingtons-disease-treatment-market/

The North America region dominated the Global by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $327 Million by 2031. The Europe region is anticipated to grow at a CAGR of 8.8% during (2024 - 2031). Additionally, The Asia Pacific region would witness a CAGR of 9.7% during (2024 - 2031).

List of Key Companies Profiled

• Bausch Health Companies, Inc.
• Teva Pharmaceutical Industries Ltd.
• Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
• Hikma Pharmaceuticals PLC
• Takeda Pharmaceutical Company Limited
• Sun Pharmaceutical Industries Ltd.
• Dr.Reddy’s Laboratories Ltd.
• Neurocrine Biosciences Inc.
• Pfizer, Inc.
• F.Hoffmann-La Roche Ltd.

Huntington’s Disease Treatment Report Segmentation

By Drug Type

• Approved Drugs
  • Tetrabenazine
  • Deutetrabenazine
• Offlabel Drugs

By Distribution Channel

• Hospital Pharmacies
• Drug Store & Retail Pharmacies
• Online Pharmacies

By Age

• Below 50 years
• Above 50 years

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Related Reports: